The EPS miss is minor for a pre-revenue biotech. The key catalyst is OCS-01 DME Phase 3 data in June 2026 — a positive readout could drive significant upside. Monitor for DIAMOND topline results as the primary near-term event. Cash runway into 2H 2029 removes financing overhang.
Price Chart
Executive Summary
Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the stock is driven by pipeline catalysts: OCS-01 DME Phase 3 topline data in June 2026, Licaminlimab DED readout around year-end, and Privosegtor SPA agreement. Cash of $277.6M provides runway into 2H 2029, reducing near-term dilution risk.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.42 vs consensus -$0.41 (2.7% miss)
- No revenue reported; pre-revenue biotech
- Cash, cash equivalents and short-term investments of $277.6M as of March 31, 2026
- OCS-01 DIAMOND Phase 3 DME trials LPLV completed; topline data expected June 2026
- Licaminlimab PREDICT-1 Phase 3 DED trial in site recruitment; topline expected year-end 2026
- Privosegtor received FDA SPA agreement for PIONEER-1 registrational trial in optic neuritis
- Net loss CHF 28.9M ($36.8M) vs CHF 33.2M ($36.9M) in Q1 2025
- R&D expenses CHF 14.0M ($17.9M), down from CHF 14.8M ($16.4M) in Q1 2025
Financial Impact
EPS miss of 2.7% is modest; cash burn ~$36.8M/quarter provides 3+ year runway
Risk Factors
- OCS-01 Phase 3 DME trials may fail to meet endpoints
- Licaminlimab PREDICT-1 DED trial may not replicate prior genotype-driven efficacy
- Privosegtor PIONEER program may face regulatory or enrollment delays
- Dilution risk from at-the-market offering program (used in Q1 2026)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $7.96 (−9.13%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.96 (−37.62%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.96 (−37.62%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $7.96 (−27.64%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $7.96 (−27.50%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $7.96 (+64.94%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.96 (−73.82%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.96 (−73.82%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $7.96 (−74.40%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $7.96 (−71.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers